Normax Biomed develops personalized mRNA cancer immunotherapies that utilize neoantigen targeting to train the immune system to specifically attack a patient's unique cancer cells. This approach addresses the limitations of traditional treatments by minimizing side effects and improving long-term survival rates for individuals living with cancer.
Funding
$331.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often have significant side effects because they can harm healthy cells along with cancerous ones. Each patient's cancer is unique, requiring personalized approaches that can precisely target malignant cells without causing widespread damage.
Solution
Normax Biomed is developing My Cancer Immunotherapies (MCI), a personalized mRNA cancer therapy designed to direct a patient's immune system to attack their specific cancer cells. This approach leverages neoantigens, unique markers found on a patient's cancer cells, to train the immune system for targeted destruction. By focusing on these specific neoantigens, the immunotherapy aims to minimize harm to healthy tissues, potentially leading to fewer side effects and improved long-term outcomes. The company's vision includes a financially scalable model for hospitals and clinics to deliver these personalized treatments, integrating AI for neoantigen discovery and digital health services.
Target Audience
The primary target audience includes oncologists, hospitals, clinics, and professional investors interested in personalized cancer treatments.
Features
- Personalized mRNA cancer therapy based on individual patient neoantigens
- AI-driven neoantigen discovery for precise targeting of cancer cells
- Designed to minimize harm to healthy cells, reducing side effects
- Potential for combination with standard treatments like surgery, radiation, and chemotherapy
- Development of automated Good Manufacturing Practices (GMP) technology for personalized drug development